Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Viewpoints
Showing 1561 - 1568 of 12143 results

Considering Converting an LLC into a Corporation? Here Are the QSBS Issues You Should Be Thinking About
August 22, 2023| Alert| Viewpoint

Law360's 2023 Telecommunications Editorial Advisory Board
August 22, 2023| News

$4.3 Million Or $1.27 Million? What’s The Point Of Scary Retirement Projection Numbers?
August 22, 2023| News

What Is A Major Advantage Of Separately Managed Accounts (SMAs)?
August 22, 2023| News

Health Law Diagnosed – CA Proposes Regs for Pre-Closing Review of Health Care Deals: What You Need to Know
August 21, 2023| Podcast| Viewpoint

FTC Proposed Settlement Requires Private Equity Firm to Divest Shares, Relinquish Potential Board Seat, and Other Expansive Remedies
August 21, 2023| Blog| Viewpoint

Can Enablement and Written Description Bars be Lower for Method-Of-Treatment Patent Claims?
August 21, 2023| Blog| Viewpoint
News & Press Releases
Mintz Advises Point72 and Tsunami Express Car Wash in Acquisition of 53 Car Wash Locations from Whistle Express Car Wash
September 16, 2025
Mintz advised Point72 and Tsunami Express Car Wash, its portfolio company, in Tsunami’s acquisition of 53 car wash locations from Whistle Express Car Wash, which is owned by affiliates of Oaktree Capital Management.
Mintz Advises Charlesbank Capital Partners on Acquisition of Q6 Cyber
September 15, 2025
Mintz Advises on LB Pharmaceuticals’ $285 Million Initial Public Offering
September 12, 2025
Mintz advised the underwriters in connection with a $285 million initial public offering by LB Pharmaceuticals Inc of 19,000,000 shares of common stock at an initial public offering price of $15.00 per share. The aggregate gross proceeds to LB Pharmaceuticals from this offering were approximately $285 million before deducting underwriting discounts and commissions and other offering expenses. In addition, LB Pharmaceuticals granted the underwriters a 30-day option to purchase up to an additional 2,850,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions. The shares began trading on the Nasdaq Global Market on September 11, 2025 under the ticker symbol “LBRX.”
Events
Podcasts

Mintz On Air: Practical Policies – DEI Developments: The Proxy Problem
September 16, 2025| Podcast|

Mintz On Air: Practical Policies – Disparage Me Not
August 26, 2025| Podcast|

Mintz On Air: Practical Policies - Investigations Unscripted
August 12, 2025| Podcast|
